BIVDA Press Releases

22Apr

Member Press Release - Stream Bio collaborates with MIP Diagnostics Ltd. on a rapid diagnostic and mass screening test for COVID-19

PRESS RELEASE

22nd April 2020

Stream Bio, a company that develops and manufactures a range of transformative bioimaging molecular probes, is delighted to announce a new joint venture with MIP Diagnostics Ltd., a world leader in molecular imprinting for diagnostic and other applications. The collaborative project will focus on the development of a COVID-19 (or SARS-Cov-2) antigen reagent for assays, a lateral flow Rapid Diagnostic Test (RDT) and an ‘ELISA’ type assay for high throughput screening (HTS) or mass testing.

The unique properties of both Stream’s and MIP’s novel technologies allows for fast development of an extremely sensitive, and stable detection platform for the virus. The lateral flow project aims to reduce the diagnosis time to just 10 minutes, while the ELISA assay would enable a different detection system common in nearly all labs to be utilised alongside PCR, dramatically increasing capability.

With current PCR-based methods, it can take over a day to receive and act on lab results. The proposed point-of-care lateral flow technology (LFT) will reduce this by more than 140 times and once validated, be deployed anywhere for ‘on-thespot’ screening, for use by first responders on scene to transit hubs and airports. The resulting LFT strip can easily be mass-produced.

In this consortium, Stream Bio’s Conjugated Polymer Nanoparticles (CPNs) will combine their capabilities for temperature stability, intense fluorescence and magnetism, with the versatile, stable molecular imprinted polymers (nanoMIPs) or synthetic ‘plastic antibodies’ from MIP Diagnostics Ltd.. The proprietary nanoMiPs work in the same way as conventional antibodies by targeting and latching onto a specific ‘binding site’ of the virus, the ‘spike’, but without the significant development timeline or immunogenic requirement.

Andy Chaloner, Founding Director and CEO of Stream Bio, commented “I am extremely excited by the possibilities of the combination of our two technologies, and the novel angle we can bring to the fight against the COVID-19 pandemic. CPNs have previously shown great capabilities in diagnostics, and implementing them in this collaboration is a huge milestone for Stream Bio.”

“This is another great opportunity for nanoMIPs to make a significant impact on diagnostics development by leveraging the fast turnaround, high robustness and sensitivity benefits of MIPs with CPNs” said Stephane Argivier, Interim CEO, MIP Diagnostics Ltd., “and we are pleased to be working with another innovative platform on this collaboration to make a significant impact on the current worldwide need for rapid test development to COVID-19 diagnosis and monitoring.”

For more information about CPNs’ benefits to LFTs and RDTs, click here. For more information and publications about nanoMIPs in various applications, click here.

About Stream Bio

At Stream Bio, we develop and manufacture a range of innovative bioimaging molecular probes that cover the visible and near infra-red spectrum, Conjugated Polymer Nanoparticles (CPNs™), for applications in R&D, in-vitro diagnostic assay’s and therapeutic research. CPN’s have superior properties to conventional probes such as an intense brightness (sensitivity), incredible stability (temperature and pH) and can be linked to a variety of targeting molecules. For more information, please visit: https://www.streambio.co.uk

For further information, images and interview opportunities with Stream Bio, please contact Shazia Ansari at Notch Communications shazia.ansari@notchcommunications.co.uk

About MIP Diagnostics Ltd.

MIP Diagnostics Limited develops and manufactures nanoMIPs, linear MIPs, bulk MIP and Rationally Designed Polymers using its proprietary processes. Molecularly Imprinted Polymers (MIPs) are ‘synthetic’ affinity reagents and the nanoMIP format provides a more robust alternative to antibodies, typically with similar or greater affinity coupled with additional unique characteristics for detection, separation, imaging, and cofactor applications. For more information about MIP Diagnostics Ltd, please visit us at https://www.mip-dx.com/

Media Contact: Lisa Thurston at MIP Diagnostics Ltd. can be contacted at enquiries@mip-dx.com or +44 (0)1234 58972

Related

Member Press Release - UK COVID-19 rapid antibody tests approved for professional use

The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer lead...

Read More >

BIVDA response to Parliament’s vote on the Brexit deal

Doris-Ann Williams, Chief Executive of BIVDA, comments on tonight's vote

Read More >

BIVDA joins declaration by industry on combating antimicrobial resistance

BIVDA has joined more than 80 leading international pharmaceutical, generics, diagnostics and biotec...

Read More >

BIVDA response to the Secretary of State for Health and Social Care's vision for prevention

Today the Secretary of State for Health and Social Care, Matt Hancock MP, has announced his vision f...

Read More >

BIVDA Comment on Prime Minister's No Deal Brexit Statement

 BIVDA has commented on the Prime Minister’s statement today declaring that the United Ki...

Read More >

BIVDA, ABPI and CRUK release briefing on new arrangements for commissioning and funding of six molecular diagnostic tests for cancer

BIVDA, ABPI and CRUK have released a stakeholder briefing to clarify the new arrangements for commis...

Read More >